PD-L1 Expression in Urothelial Carcinoma with Predominant or Pure Variant Histology: Concordance Among Three Commonly Used and Commercially Available Antibodies

The introduction of immune checkpoint blockade (ICB) therapy has transformed the management of advanced bladder cancer (BC). Despite its limitations, PD-L1 immunohistochemistry may serve as a predictive biomarker of anti-PD-L1/PD1 therapy. While urothelial carcinoma (UC) patients with predominant or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Surg Pathol
Main Authors: Reis, Henning, Serrette, Rene, Posada, Jennifer, Lu, Vincent, Chen, Ying-bei, Gopalan, Anuradha, Fine, Samson W., Tickoo, Satish K., Sirintrapun, S. Joseph, Iyer, Gopa, Funt, Samuel A., Teo, Min Yuen, Rosenberg, Jonathan E., Bajorin, Dean F., Dalbagni, Guido, Bochner, Bernard H., Solit, David B., Reuter, Victor E., Al-Ahmadie, Hikmat A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561805/
https://ncbi.nlm.nih.gov/pubmed/31135485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAS.0000000000001264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados